Clinical trials are expensive. Cardiocel will be running itself a profit by next year, and a successful HSV2 trial will be why we need the next CR. I can't see that being a negative to the share price. If HSV is not successful it stops a significant porportion of that burn.
Clinical trials are expensive. Cardiocel will be running itself...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.80 |
Change
-0.200(1.67%) |
Mkt cap ! $249.4M | |||
| Open | High | Low | Value | Volume |
| $12.49 | $12.99 | $11.63 | $303.4K | 24.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $11.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 849 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |